News Briefs: GE launches first clinical IS product
GE Medical Systems has entered the market for clinical information systems with the launch of Integriti at the HIMSS meeting in New Orleans. Integriti is based on a clinical information system developed by SEC, a software firm acquired by GE in November.
GE Medical Systems has entered the market for clinical information systems with the launch of Integriti at the HIMSS meeting in New Orleans. Integriti is based on a clinical information system developed by SEC, a software firm acquired by GE in November. The first part of Integriti was piloted in 1994 at the University of Michigan Health System, where it is used in the emergency room, intensive care, operating rooms, and related outpatient clinics. SEC installed the system at other Midwestern hospitals as well, but GE plans to roll it out nationally, according to Greg Lucier, president and CEO of GE Medical Systems Information Technologies. The University of Michigan is also looking to expand its implementation with a portal for referring physicians and patients.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
